Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC).

This multicenter retrospective study by GETH-TC validates the prognostic value of the Allo-HCT Refined ELN 2022 risk classification in allografted AML patients. The new classification refines the ELN 2022 risk classification, dividing adverse-risk patients into two subgroups: Adv-Plus (AdvP), includ...

ver descrição completa

Detalhes bibliográficos
Autores: Jiménez-Vicente, Carlos, Esteve, Jordi, Baile-González, Mónica, Pérez-López, Estefanía, Martin Calvo, Carmen, Aparicio, Clara, Oiartzabal Ormategi, Itziar, Esquirol, Albert, Peña-Muñoz, Felipe, Fernández-Luis, Sara, Heras Fernando, Inmaculada, González-Rodríguez, Ana Pilar, López-García, Alberto, López-Lorenzo, Jose Luis, Torrado, Tamara, Sáez Marín, Adolfo Jesús, Acosta Fleytas, Cynthia, Garcia-Maño, Lucia, Villar, Sara, Filaferro, Silvia, Balsalobre, Pascual, Pascual Cascón, María Jesús, Salas, María Queralt
Formato: artículo
Fecha de publicación:2025
País:España
Recursos:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/25039
Acesso em linha:https://hdl.handle.net/20.500.13003/25039
Access Level:acceso abierto
Palavra-chave:Adolescent
Adult
Aged
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myelomonocytic, Acute
Male
Middle Aged
Prognosis
Retrospective Studies
Risk Assessment
Risk Factors
Spain
Transplantation, Homologous
Young Adult
Adolescente
Adulto
Anciano
Femenino
Trasplante de Células Madre Hematopoyéticas
Humanos
Leucemia Mielomonocítica Aguda
Masculino
Persona de Mediana Edad
Pronóstico
Estudios Retrospectivos
Medición de Riesgo
Factores de Riesgo
España
Trasplante Homólogo
Adulto Joven
Descrição
Resumo:This multicenter retrospective study by GETH-TC validates the prognostic value of the Allo-HCT Refined ELN 2022 risk classification in allografted AML patients. The new classification refines the ELN 2022 risk classification, dividing adverse-risk patients into two subgroups: Adv-Plus (AdvP), including those with complex karyotype, MECOM (EVI1) rearrangement, or TP53 mutations/del(17p), and an additional adverse group (Adv*). The study included 651 AML patients treated with at least one line of anthracycline-based induction therapy and in complete remission. According to the Allo-HCT Refined ELN 2022 risk classification, 19.4% (n = 126) patients were classified into the Favorable (Fav) risk, 38.1% (n = 248) into the Intermediate (Int) risk, 27.2% (n = 177) in the Adv* and 15.4% (n = 100) in the AdvP. Outcomes were significantly poorer for patients allocated in the AdvP risk group (5-year OS rate: 32.3%, 5-year LFS rate: 24.3%, both p < 0.001 with the rest of subgroups) and a higher CIR (5-year CIR: 64.3%, p < 0.001). Patients in the Adv* risk group had similar outcomes than patients in the Int risk group (5-year OS rate: 70.2% vs. 66.7%, p = 0.69, 5-year LFS rate: 63.8% vs. 55.9%, p = 0.33). Multivariate analysis confirmed the dismal outcomes for AdvP patients for OS: Hazard Ratio (HR) = 3.05, and LFS: HR = 2.66, both p < 0.001. Our findings validate the Allo-HCT Refined ELN 2022 classification as a robust prognostic tool, particularly highlighting the poor outcomes for the AdvP subgroup.

Registos relacionados